# BioLineRx Ltd.: overview BLRX · Nasdaq · CIK 1498403 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/blrx.md) · [Financials](/companies/blrx/financials.md) · [Filings](/companies/blrx/filings.md) · [Insiders](/companies/blrx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001178913-24-001095.md) | [0.0](/filings/0001178913-25-001123.md) | [4.8](/filings/0001178913-26-001581.md) | [28.9](/filings/0001178913-26-001581.md) | [1.2](/filings/0001178913-26-001581.md) | | Gross margin | % | not reported | not reported | [23.1%](/filings/0001178913-26-001581.md) | [68.0%](/filings/0001178913-26-001581.md) | [80.5%](/filings/0001178913-26-001581.md) | | Operating margin | % | not reported | not reported | [(1035.3%)](/filings/0001178913-26-001581.md) | [(70.5%)](/filings/0001178913-26-001581.md) | [(871.8%)](/filings/0001178913-26-001581.md) | | Net margin | % | not reported | not reported | [(1262.8%)](/filings/0001178913-26-001581.md) | [(31.9%)](/filings/0001178913-26-001581.md) | [(171.7%)](/filings/0001178913-26-001581.md) | | Diluted EPS | $ per share | [(0.04)](/filings/0001178913-24-001095.md) | [(0.03)](/filings/0001178913-25-001123.md) | [(0.06)](/filings/0001178913-26-001581.md) | [(0.01)](/filings/0001178913-26-001581.md) | [0.00](/filings/0001178913-26-001581.md) | | Free cash flow | $m | [(23.7)](/filings/0001178913-24-001095.md) | [(26.4)](/filings/0001178913-25-001123.md) | [(22.7)](/filings/0001178913-26-001581.md) | [(43.9)](/filings/0001178913-26-001581.md) | [(8.1)](/filings/0001178913-26-001581.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/blrx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $120.9k | 39,000 | Call | Added +28,800 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $95.8k | 30,911 | | New +30,911 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $48.1k | 15,412 | | New +15,412 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $45.9k | 14,796 | | New +14,796 | | [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $7.7k | 2,478 | | Added +125 | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $6.2k | 2,000 | | Added +250 | | [BNP PARIBAS FINANCIAL MARKETS](/funds/1166588.md) | 2026-06-30 | $1.6k | 500 | | Reduced −1,300 | | [Banque Cantonale Vaudoise](/funds/1793755.md) | 2026-06-30 | $1.0k | 1 | | Unchanged | | [Nemes Rush Group LLC](/funds/1982273.md) | 2026-06-30 | $780 | 250 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $315 | 101 | | Reduced −428 | ## Recent filings [All 616 filings](/companies/blrx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 07:05 ET | [6-K](/filings/0001178913-26-004823.md) | Report of a foreign private issuer, period 2026-10-23 | 0001178913-26-004823 | | 2026-09-24 | 20:04 ET | [6-K](/filings/0001178913-26-004591.md) | Report of a foreign private issuer, period 2026-09-24 | 0001178913-26-004591 | | 2026-09-10 | 11:00 ET | [6-K](/filings/0001178913-26-004479.md) | Report of a foreign private issuer, period 2026-09-10 | 0001178913-26-004479 | | 2026-08-31 | 14:23 ET | [6-K](/filings/0001178913-26-004334.md) | Report of a foreign private issuer, period 2026-08-31 | 0001178913-26-004334 | | 2026-08-31 | 11:15 ET | [6-K](/filings/0001178913-26-004331.md) | Report of a foreign private issuer, period 2026-06-30 | 0001178913-26-004331 | | 2026-08-28 | 12:12 ET | [6-K](/filings/0001178913-26-004292.md) | Report of a foreign private issuer, period 2025-08-28 | 0001178913-26-004292 | | 2026-08-18 | 20:04 ET | [6-K](/filings/0001178913-26-004184.md) | Report of a foreign private issuer, period 2026-08-18 | 0001178913-26-004184 | | 2026-07-08 | 11:08 ET | [6-K](/filings/0001178913-26-003438.md) | Report of a foreign private issuer, period 2026-07-08 | 0001178913-26-003438 | | 2026-05-27 | 11:19 ET | [6-K](/filings/0001178913-26-002934.md) | Report of a foreign private issuer, period 2026-05-27 | 0001178913-26-002934 | | 2026-05-22 | 11:00 ET | [6-K](/filings/0001178913-26-002876.md) | Report of a foreign private issuer, period 2026-05-22 | 0001178913-26-002876 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001178913-26-001581.md), filed Mar 23, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1498403 - Tickers: BLRX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: L3 - Filer category: Non-accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.